Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
186Re-bivatuzumab
- Development stage
- Unknown
- Lead developer
- Boehringer Ingelheim
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
186Re-bivatuzumab is a radiopharmaceutical consisting of the humanized monoclonal antibody bivatuzumab (BIWA 4) labeled with the radioisotope rhenium-186. It targets CD44v6, which is expressed in squamous cell carcinomas of the head and neck and other epithelial cancers. The drug delivers targeted radiation therapy to tumor cells expressing CD44v6.
- Other names
- 186Re-labeled bivatuzumab
02
Targets
CD44v6 (CD44 variant isoform 6)
Beyond the preview
Go deeper on 186Re-bivatuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 186Re-bivatuzumab.